Coronavirus Latest News
Pfizer raises Covid-19 vaccine sales forecast to $36bn for 2021
US drugmaker expects to manufacture 3bn doses of vaccine with BioNTech this year
The US drugmaker Pfizer has lifted its 2021 forecast for revenues from its Covid vaccine to $36bn (£26.3bn), and forecast another $29bn sales next year after it started shipping booster jabs and shots for children.
The Covid jab, called Comirnaty and developed with Germany’s BioNTech, contributed $13bn of revenues in the three months to 30 September. That was more than half of Pfizer’s total revenues of $24bn in the quarter, which rose 134% from a year earlier. In the first six months of the year, Corminaty revenues were $11.3bn.
Read the original article at The Guardian